Radioimmunoassay for fluoxymesterone (Halotestin).

Area of Science:

• Endocrinology
• Analytical Chemistry
• Pharmacology

Background:

• Fluoxymesterone (Halotestin) is an anabolic-androgenic steroid with therapeutic and performance-enhancing applications.
• Accurate quantification of fluoxymesterone is crucial for pharmacokinetic studies and clinical monitoring.
• Existing methods may lack the sensitivity or specificity required for precise measurement in biological matrices.

Purpose of the Study:

• To develop and validate a specific, sensitive, precise, and accurate radioimmunoassay for fluoxymesterone.
• To establish a method capable of detecting low concentrations of fluoxymesterone in unextracted serum.
• To determine blood levels of fluoxymesterone in human subjects and dogs following oral administration.

Main Methods:

• Development of a radioimmunoassay using an antibody raised against fluoxymesterone 3-(0-(carboxy-methoxime)) (CMO) conjugated to bovine serum albumin.
• Characterization of assay specificity, focusing on the influence of hydroxyl and methyl groups on antibody binding.
• Quantification of fluoxymesterone in 0.1 ml of unextracted serum, with a detection limit of 25 picograms.

Main Results:

• The developed radioimmunoassay demonstrated high specificity, with minimal cross-reactivity from physiological levels of endogenous steroids.
• The assay achieved a detection limit of 25 picograms of fluoxymesterone per 0.1 ml of serum.
• Blood levels of fluoxymesterone were successfully determined in both human and male beagle dog subjects after oral Halotestin administration.

Conclusions:

• A robust radioimmunoassay for fluoxymesterone (Halotestin) has been successfully developed and validated.
• The assay's specificity is significantly influenced by key structural features of fluoxymesterone, ensuring reliable measurement.
• This method provides a valuable tool for pharmacokinetic and pharmacodynamic investigations of fluoxymesterone in clinical and preclinical settings.